All NET patients globally are invited to share their experiences and perspectives on how treatment decisions have been modified during the COVID-19 pandemic for them via a specially designed survey. The survey is available in English, French, Italian and Spanish, and is developed by NET CONNECT, a group of both established and next-generation international experts in the field of neuroendocrine tumors (NET). INCA is a proud partner of NET Connect.

The survey is open by July 15th.

Take the survey.